BioMarin shares five-year Pompe disease drug data at muscle congress
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) presented five-year Phase 3 open-label extension data for its two-drug combination Pombiliti (cipaglucosidase alfa-atga) and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




